Important Safety Information (cont’d)

• It is not known whether SHINGRIX is excreted in human milk. Data are not available to assess the effects of SHINGRIX on the breastfed infant or on milk production/excretion
• Vaccination with SHINGRIX may not result in protection of all vaccine recipients

Please see Important Safety Information throughout and accompanying full Prescribing Information, also available at SHINGRIXHCP.com.
UNDERSTANDING SHINGLES & AGING

- 99% of people ≥50 years old have had chickenpox, so the virus that causes shingles is already inside their body.4
- In 1 out of 3 people, the dormant virus reactivates and causes shingles.4
- As immunity against the virus decreases with age, the risk of reactivation increases.6,8

WHEN TO RECOMMEND SHINGRIX

- Unlike seasonal vaccines, the SHINGRIX series can be recommended at any time of the year.2
- The best time to recommend SHINGRIX is any time you are meeting with your adult patients in person or virtually.

GETTING YOUR PATIENTS VACCINATED ANY TIME OF YEAR

Optimizing the SHINGRIX Referral Process With 4 Simple Steps:

1. Provide a strong recommendation
   A strong recommendation can increase the likelihood your patient takes action to get vaccinated, so it’s important to make it clear that getting SHINGRIX is the best way to prevent shingles.10,11

2. Write an eScript for SHINGRIX
   The CDC suggests providing a prescription with your vaccine referral. This can reinforce your recommendation and motivate patients to follow through on receiving their first dose of SHINGRIX.7

3. Discuss what to expect with patients
   Because SHINGRIX is a 2-dose series, it’s important to set expectations, so walk patients through the dosing, administration, and common side effects of SHINGRIX, and emphasize the importance of getting both doses.1

4. Follow up with each patient
   Following up with patients about their series completion during their next office visit helps to reinforce the urgency of being protected from shingles.7

Important Safety Information (cont’d)

- Syncope (fainting) can be associated with the administration of injectable vaccines, including SHINGRIX. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncpe.

Please see Important Safety Information throughout and accompanying full prescribing information, also available at SHINGRIXHCP.com.

PATIENT ENGAGEMENT

Topics to discuss with your adult patients

Inform patients of the potential benefits and risks of immunization with SHINGRIX.

Shingles

Disease

Risk

Talk about the risk of shingles for those who have had chickenpox.4

Efficacy

SHINGRIX delivered >90% efficacy against shingles regardless of age in those 50 years and older.1,4

Safety and Tolerability

The local and general adverse reactions seen with SHINGRIX had a median duration of 2 to 3 days.1

What to Expect

Your patient may experience side effects after receiving SHINGRIX. In clinical trials, the most common side effects were pain, redness, and swelling at the injection site, muscle pain, tiredness, headache, shivering, fever, and upset stomach.1

SHINGRIX had a median duration of 2 to 3 days.1

2-DOSE SERIES

SHINGRIX is a 2-dose series, with the second dose given 2 to 6 months after the first dose. It is important to receive both doses. The efficacy results of SHINGRIX were demonstrated in clinical trials when administered as a 2-dose series.1

DOSSING SCHEDULE

Jan Feb Mar Apr May Jun Jul Aug

DOSE 1 DOSE 2

Month 0 2 to 6 months

RECOMMEND WITH CERTAINTY – SHINGRIX IS $0 FOR NEARLY ALL PATIENTS 50 AND OLDER9-11

For your patients with commercial insurance plans:

More than 9 out of 10 are covered, with average copays just [$4] or less.9,10

95% of commercial patients pay $0 for SHINGRIX.9,10

For your Medicare Part D patients:

Great coverage is now even better: Due to the Inflation Reduction Act, all Medicare Part D patients can now get SHINGRIX for $0 through their pharmacy.9,10

Important Safety Information (cont’d)

- The data are insufficient to establish if there is vaccine-associated risk with SHINGRIX in pregnant women.

References:


11. Managed Markets Insight & Technology, LLC. Database as of October 2022.